Takeda is a global research and development-driven pharmaceutical company headquartered in Japan. The company is committed to bringing «Better Health and a Brighter Future» to people worldwide. ...
In our newest publication «IFBC Review» we describe selected projects in the areas of Corporate Finance and M&A, Performance and Financial Risk Management as well as IFRS Advisory that we successfully...
After a pandemic-related decline in M&A activity, particularly in the second quarter of 2020, both the observable transaction volume and the number of announced transactions increased significantly again in 2021. For...
On 31 March 2022, Burkhalter Holding Ltd (Burkhalter) and poenina holding ltd (Poenina) announced their intention for a joint merger with completion by the end of June 2022. The evaluation of...
The European Life Sciences & Healthcare sector is currently confronted with various trends and challenges, all of which emphasize the dynamic environment as well as the major changes emerging in the...
Following a problem-ridden 2020 a hopeful first half of 2021 recorded a recovery of the global economy at record speed and rising stock markets....
Markus Naef, CEO of SwissSign Group AG until December 2021, describes his experiences in connection with the successful transaction....
We are pleased to invite you to our seminar on the topics «Corporate transactions and valuation»...
In the following, we look back on an active M&A year 2021 in Switzerland and dare an outlook on the expected M&A activities in 2022....
On 14 December 2021, CSL Limited announced its offer to acquire all publicly held registered shares of Vifor Pharma Ltd. (Vifor Pharma) through its subsidiary CSL Behring AG (CSL) by means...
In the following interview, Adrian Eggenberger, Head of Corporate Clients at Schwyzer Kantonalbank, provides interesting insights on the current challenges in corporate banking and the project in collaboration with IFBC....
In the fourth part of our blog series on “Company value and offer price in the context of public takeovers,” we discuss what to look out for in the special topics...